Author:
Razak Albiruni R. Abdul,Wang Hung-Ming,Chang Jang-Yang,Ahn Myung-Ju,Munster Pamela,Blumenschein George,Solomon Benjamin,Lim Darren Wan-Teck,Hong Ruey-Long,Pfister David,Saba Nabil F.,Lee Se-Hoon,van Herpen Carla,Quadt Cornelia,Bootle Douglas,Blumenstein Lars,Demanse David,Delord Jean-Pierre
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference31 articles.
1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695–709.
2. Malone E, Siu LL. Precision medicine in head and neck cancer: myth or reality? Clin Med Insights Oncol. 2018;12:1179554918779581.
3. National Comprehensive Cancer Network clinical practice guideline in oncology (NCCN guideline®). Head and neck cancers. Version 1.2018—Feb 15, 2018. https://oncolife.com.ua/doc/nccn/Head_and_Neck_Cancers.pdf. Accessed 3 June 2022.
4. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708.
5. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–7.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献